MDMA (ecstasy) is a widely used recreational stimulant. Users often combine it with other drugs to enhance effects, reduce toxicity, or manage comedowns, which increases the risk of severe toxicity. This review covers known interactions between MDMA and other pharmaceuticals or drugs of abuse, offering clinical recommendations. The authors note that few published studies exist and documented clinically significant interactions are scarce. Experimental evidence shows that interactions are especially relevant when MDMA is taken with drugs metabolized by the CYP2D6 enzyme, due to MDMA's inhibitory effect, and during repeated MDMA use.
MDMA (ecstasy) produces amphetamine-like euphoria and well-being, increases empathy, and induces pro-social effects that drive recreational use and suggest therapeutic potential. This review examines interindividual differences in MDMA's pharmacodynamics, focusing on sex-gender, race-ethnicity, genetic differences, interactions, acute toxicity, and therapeutic use. Acute MDMA effects are more pronounced in women than men. Very limited data exist on race-ethnicity effects. MDMA metabolism involves polymorphic enzymes that slightly alter plasma concentrations and effects. The small number of subjects in acute-effect trials limits evaluation of interindividual factors and prevents clear conclusions about their influence, which should be considered in therapeutic studies.